U.S. Pressure Clouds GSK's Outlook -- Market Talk

Dow Jones12-22 19:39

1139 GMT - GSK faces uncertainty after agreeing to lower drug prices for U.S. patients, AJ Bell's Russ Mould writes in a note. Under pressure from the Trump administration, the British pharmaceutical group has also committed to launching a direct purchasing platform and strengthening U.S. drug supply chains, Mould notes. "The company has taken these steps to avoid being hit by tariffs, having already committed to significant capital expenditure across the Atlantic with the same goal." However, it remains unclear how these measures will affect GSK's profitability or how they compare with its level of investment in and commitment to the U.K., he adds. Shares are down 0.3% at 18.17 pounds. (najat.kantouar@wsj.com)

(END) Dow Jones Newswires

December 22, 2025 06:39 ET (11:39 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment